Reply to Rahbar K et al

Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):168-169. doi: 10.1007/s00259-016-3531-1. Epub 2016 Oct 1.

Authors

Madhav Prasad Yadav¹, Sanjana Ballal¹, Madhavi Tripathi¹, Chandrasekhal Bal²

Affiliations

¹ Department of Nuclear Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.
² Department of Nuclear Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India. csbal@hotmail.com.

PMID: 27695908
DOI: 10.1007/s00259-016-3531-1

No abstract available

Publication types

Letter

MeSH terms

Bone Neoplasms / radiotherapy*
Bone Neoplasms / secondary*
Dipeptides / therapeutic use*
Heterocyclic Compounds, 1-Ring / therapeutic use*
Humans
Lutetium
Male
Outcome Assessment, Health Care / methods*
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant / radiotherapy*
Radiopharmaceuticals / therapeutic use
Radiotherapy / methods*
Treatment Outcome

Substances

177Lu-PSMA-617
Dipeptides
Heterocyclic Compounds, 1-Ring
Radiopharmaceuticals
Lutetium
Prostate-Specific Antigen